TELA Bio Ousts CEO Antony Koblish, Appoints Heather Getz with Aggressive Equity Package
TELA sits 46% above its 52-week low of $0.501.
Summary
TELA Bio fired CEO Antony Koblish and appointed Heather Getz, granting her an equity package equal to ~6.3% of outstanding shares with a Top-Up provision to maintain 5% ownership post-financing, as the company battles financial distress.
Key Events · Executive and Board Changes · TELA
-
CEO Termination
Antony Koblish removed as CEO and resigned from the Board effective August 3, 2026; termination treated as without cause.
-
New CEO Appointment
Heather Getz appointed CEO and Class II director; brings 25+ years of healthcare turnaround experience, including growing BioTelemetry from $50M to $2.8B market cap.
-
Compensation Package
Getz Employment Agreement: $650,000 base salary, 100% target bonus, severance up to 18 months upon change of control termination.
-
Initial Equity Grants
Granted 1,365,000 standard options (exercise at closing price on grant date), 1,005,000 premium options (exercise at greater of $0.90 or 15% premium to FMV), and 500,000 RSUs, vesting over 4 years.
Analysis · TELA · Industrial Applications And Services
TELA Bio abruptly terminated CEO Antony Koblish and replaced him with Heather Getz, a seasoned healthcare executive. The move comes as the company faces severe financial distress—negative stockholders' equity, a Nasdaq delisting notice, and a stock price near $0.73. Getz's employment agreement includes a $650,000 salary, a 100% target bonus, and an initial equity grant of 2.87 million shares in options and RSUs, representing roughly 6.3% of the current outstanding shares. A Top-Up provision guarantees her additional grants to maintain 5% ownership after any future financing, aligning her incentives with a turnaround but also signaling potential dilution ahead. The leadership change is a high-stakes bet on Getz's track record of turning around distressed medical device companies.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40% of the 1112 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELA was trading at $0.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $33.1M. The 52-week trading range was $0.50 to $2.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.